QSAR Studies and Scaffold Optimization of Predicted Novel ACC 2 Inhibitors to treat Metabolic Syndrome.
Kirtika MadanSarvesh PaliwalSwapnil SharmaSeema KesarMansi MadanPublished in: Current drug discovery technologies (2023)
The compounds designed in the present study have tremendous potential to yield orally active ACC 2 inhibitors to treat metabolic syndrome.